LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sheffield NHS Lab Moves to Advanced Micorarrays Platform

By LabMedica International staff writers
Posted on 08 Feb 2015
Print article
A case study discusses Sheffield laboratory’s experience of switching to a more efficient and reliable microarrays platform for cytogenetic research.

Advances in array design and analysis capabilities mean that choosing a platform can be challenging. A new case study by Oxford Gene Technology (OGT; Oxfordshire, UK) explores how Sheffield Children's NHS Foundation Trust (UK) has seamlessly transferred to its CytoSure ISCA 8x60k platform. Upon a highly stringent National Health Service (NHS, UK) tender for the supply of oligo-based cytogenetics research arrays, CytoSure was selected based on the quality of data and analysis software. It was the only platform able to correctly identify all the genetic abnormalities tested.

The NHS carried out a comprehensive comparison of multiple array platforms in order to select the most effective solution (considering quality of results, ease of use and cost) via a consortium led by four prominent laboratories. Chosen over alternatives, the success of the CytoSure ISCA array, designed in partnership with the International Collaboration for Clinical Genomics (ICCG), was attributed to a combination of the array and CytoSure Interpret Software performance. Every lab submitted a set of challenging samples to be processed by OGT, and the results came back clean and clear, with the data interpretation software greatly facilitating analysis.

Maintaining productivity within the laboratory, OGT worked hard to ensure a seamless transfer process. In addition to getting the new system itself up and running, the team also provided on-site operational training, software tutorials, and transfer of local legacy data to the CytoSure Interpret Software database. “I can only be extremely positive about the whole process of switching to OGT’s CytoSure platform, so if anyone asks me if it’s worth the time and effort of transferring, the answer is a clear yes,” said Kath Smith, consultant clinical scientist at Sheffield’s. James Clough, Executive Vice President Commercial at OGT, commented, “It’s a pleasure to welcome Sheffield Children's NHS Foundation Trust to OGT. Customer satisfaction is extremely important to us, so it’s great to get such positive feedback on our products and support. It’s a testament to our team’s hard work and dedication.”

A 3 month data audit has revealed more accurate aneuploidy calling, leading to fewer uncertain cases and saving time and resources involved in follow-up investigations. The switch has also benefited Sheffield’s lab from the practicality of high-throughput plate-based labeling through to enhancing its overall operation in a more cost-effective manner.

CytoSure is provided under an agreement between Agilent Technologies and OGT. The product is for research use only and not for diagnostic or other medical use.

Related Links:

Oxford Gene Technology
Evaluating and switching to CytoSure microarrays, OGT case study 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more